Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand.
Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand.
Nat Rev Rheumatol. 2022 Oct;18(10):603-609. doi: 10.1038/s41584-022-00816-1. Epub 2022 Aug 16.
Gout management involves two broad aspects: treatment of gout flares to provide rapid symptomatic relief and long-term urate-lowering therapy to lower serum urate sufficiently to prevent gout flares from occurring. All of the major rheumatology societies recommend a target serum urate of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), both of which are below the point of saturation for urate and therefore lead to monosodium urate crystal dissolution. In this Review, we describe the rationale for treat-to-target urate approach in the long-term management of gout and the current evidence and controversy around the appropriate serum urate targets.
痛风发作的治疗以提供快速的症状缓解,以及长期的尿酸降低治疗以充分降低血清尿酸水平,从而预防痛风发作的发生。所有主要的风湿病学会都建议将目标血清尿酸水平<5mg/dl(<0.30mmol/l)或<6mg/dl(<0.36mmol/l),这两个水平都低于尿酸的饱和度,因此导致单钠尿酸盐晶体溶解。在这篇综述中,我们描述了在痛风的长期管理中采用达标治疗尿酸的原理,以及目前在适当的血清尿酸目标方面的证据和争议。